The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
1 Primary · 3 Secondary · Reporting Duration: Up to Month 6
Experimental Treatment
Non-Treatment Group
350 Total Participants · 4 Treatment Groups
Primary Treatment: Tigulixostat 200mg · Has Placebo Group · Phase 3
Age 18 - 85 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: